What Corolabs does

Corolabs is a private, for-profit medical device / drug-delivery company headquartered in Migdal HaEmek, Israel. Per its firmographic description, the company develops proprietary inhalation systems specifically engineered to deliver medications to the alveoli — the deep gas-exchange regions of the lung — positioning it in the targeted pulmonary drug-delivery niche rather than conventional upper-airway or systemic inhalation therapy.

The company is founder-led: Asaf Weinberger is listed as Founder & CEO. No additional management, scientific advisors, board members, headcount, funding rounds, or strategic investors are disclosed in the available source material. There is no evidence of named customers, commercial products in market, partnership agreements, regulatory submissions, clinical milestones, patents, or certifications. The only verifiable public web presence captured in the input data is a listing on HugeDomains offering the corolabs.com domain for sale at $11,395, with that listing representing the domain registrar's commerce page rather than any corporate activity by Corolabs.

Because the source data contains no revenue, pricing, GTM, or product-portfolio detail, the company's current commercial stage cannot be reliably established. What can be stated with confidence is the company's stated technical focus (alveolar-targeted inhalation delivery), its jurisdiction (Israel), its founder identity, and its private, for-profit status. Any further inference on funding stage, burn rate, or runway would exceed the evidence available.

Name

Corolabs

Website

https://corolabs.com

Company type

Private

Operating status

Operating

Short description

Corolabs is a private Israeli company developing proprietary inhalation systems engineered to deliver medications directly to the alveoli for targeted pulmonary drug delivery.

Ownership category

akta.pro rank

Product category

Pulmonary Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)

akta.pro secondary industry

Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE)

Keywords

• Inhaled drug delivery
• Pulmonary therapeutics
• Alveolar drug delivery
• Inhalation medical devices
• Respiratory drug delivery

Headquarters

HQ city

Migdal Hameq

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Pricing tiers

Core offering

Corolabs specializes in proprietary inhalation systems specifically designed to deliver medications to the alveoli. The company's offering centers on a targeted pulmonary drug-delivery device platform intended for therapeutic use cases requiring deep-lung (alveolar) deposition of medication.

Product overview

The source data does not contain information about Corolabs's actual products or services. The page is from HugeDomains.com selling the domain name "CoroLabs.com" for $11,395. No product or service portfolio for Corolabs is described in this source.

Differentiator

Problem solved

Functional benefit

Products and services

• Proprietary Inhalation System for Alveolar Drug Delivery

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• United Therapeutics: Develops inhaled therapeutics such as Tyvaso DPI for pulmonary hypertension, operating device-plus-formulation inhaled programs analogous to where Corolabs' platform could be applied.
• Omron Healthcare: Established manufacturer of consumer and clinical nebulizers; relevant comparable for the inhalation device category, though Corolabs' alveolar-targeting technology would be more specialized.
• Vapotherm: Markets high-flow respiratory drug delivery systems; shares the respiratory drug-delivery category and serves overlapping hospital/clinical customers.
• Philips Respironics: Large incumbent offering inhalation/nebulizer devices and ventilation solutions as part of a broader respiratory portfolio; overlaps with Corolabs on device-based drug delivery but covers a much wider product range.

Direct peers

• PARI Medical (PARI GmbH): Specialist manufacturer of nebulizers and aerosol drug delivery systems for respiratory care, including devices engineered for deep-lung deposition — directly comparable to Corolabs' inhalation systems focus.
• Aerogen: Developer of vibrating mesh nebulizer technology used in acute care and home settings to deliver drugs deep into the lungs; comparable as a device-only inhalation delivery company targeting alveolar deposition.

Emerging players

• Insmed: Pursues inhaled formulations (e.g., ARIKAYCE) delivered to deep lung tissue using advanced nebulizer platforms — directly analogous alveolar-targeted strategy with a working drug-device combination.
• Civitas Therapeutics (acquired by Acorda): Built an inhaled levodopa (ARCUS) platform targeting deep-lung delivery for Parkinson's; matches Corolabs' combination-product inhaled delivery thesis on a different therapeutic target.
• Respira Therapeutics: Early-stage company working on inhaled therapeutics for pulmonary disease; relevant as a similarly sized emerging inhaled-drug-delivery peer in the same category.
• Dance Biopharm: Developed a soft-mist inhaled insulin/biologics platform; comparable as a focused drug-device company pursuing deep-lung delivery rather than competing across broad respiratory categories.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corolabs